logo-loader

Full interview: PDS Biotech preparing to initiate three phase two clinical studies for lead candidate PDS0101 in partnership with leading oncology institutions

Published: 11:06 03 Mar 2020 EST

PDS Biotechnology (NASDAQ-PDSB) CEO Frank Bedu-Addo sat down with Steve Darling from Proactive in New York to discuss the company that had an unexpected discovery that positively charged cationic lipids, being studied in the unrelated field of gene therapy.

Bedu-Addo telling Proactive where their products are in the pipeline and also about some of the clinical studies that are underway and about to begin. 

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

8 hours, 6 minutes ago